<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#Cover" roleURI="http://mirapharmaceuticals.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#BalanceSheets" roleURI="http://mirapharmaceuticals.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#BalanceSheetsParenthetical" roleURI="http://mirapharmaceuticals.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#StatementsOfOperations" roleURI="http://mirapharmaceuticals.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#CodensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://mirapharmaceuticals.com/role/CodensedConsolidatedStatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#StatementsOfCashFlows" roleURI="http://mirapharmaceuticals.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://mirapharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#PrepaidExpenses" roleURI="http://mirapharmaceuticals.com/role/PrepaidExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#LicenseAgreementRelatedParty" roleURI="http://mirapharmaceuticals.com/role/LicenseAgreementRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#AssetAcquisitionAndShort-termInvestmentRelatedParty" roleURI="http://mirapharmaceuticals.com/role/AssetAcquisitionAndShort-termInvestmentRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#RelatedPartyTransactions" roleURI="http://mirapharmaceuticals.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#CommitmentsAndContingencies" roleURI="http://mirapharmaceuticals.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#StockholdersEquity" roleURI="http://mirapharmaceuticals.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#SegmentInformation" roleURI="http://mirapharmaceuticals.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#SubsequentEvents" roleURI="http://mirapharmaceuticals.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://mirapharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://mirapharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#PrepaidExpensesTables" roleURI="http://mirapharmaceuticals.com/role/PrepaidExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#AssetAcquisitionAndShort-termInvestmentRelatedPartyTables" roleURI="http://mirapharmaceuticals.com/role/AssetAcquisitionAndShort-termInvestmentRelatedPartyTables" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#StockholdersEquityTables" roleURI="http://mirapharmaceuticals.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#SegmentInformationTables" roleURI="http://mirapharmaceuticals.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#ScheduleOfDilutedNetLossPerShareAttributedToCommonStockDetails" roleURI="http://mirapharmaceuticals.com/role/ScheduleOfDilutedNetLossPerShareAttributedToCommonStockDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://mirapharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#ScheduleOfPrepaidExpensesDetails" roleURI="http://mirapharmaceuticals.com/role/ScheduleOfPrepaidExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#LicenseAgreementRelatedPartyDetailsNarrative" roleURI="http://mirapharmaceuticals.com/role/LicenseAgreementRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#ScheduleOfConsolidatedFinancialStatementsDetails" roleURI="http://mirapharmaceuticals.com/role/ScheduleOfConsolidatedFinancialStatementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#AssetAcquisitionAndShort-termInvestmentRelatedPartyDetailsNarrative" roleURI="http://mirapharmaceuticals.com/role/AssetAcquisitionAndShort-termInvestmentRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://mirapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#ScheduleOfOptionActivityDetails" roleURI="http://mirapharmaceuticals.com/role/ScheduleOfOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#ScheduleOfRestrisctedStockUnitActivityDetails" roleURI="http://mirapharmaceuticals.com/role/ScheduleOfRestrisctedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://mirapharmaceuticals.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://mirapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#ScheduleOfSegmentExpensesAndOtherSegmentExpensesDetails" roleURI="http://mirapharmaceuticals.com/role/ScheduleOfSegmentExpensesAndOtherSegmentExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#SegmentInformationDetailsNarrative" roleURI="http://mirapharmaceuticals.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mira-20260630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://mirapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mira-20260630.xsd#MIRA_AccruedCompensationRelatedParty" xlink:label="loc_MIRAAccruedCompensationRelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_MIRAAccruedCompensationRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mira-20260630.xsd#MIRA_AdvancePayableToRelatedParty" xlink:label="loc_MIRAAdvancePayableToRelatedParty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_MIRAAdvancePayableToRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/CodensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Codensed Consolidated Statements of Changes In Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mira-20260630.xsd#MIRA_PaymentOfDeferredOfferingCosts" xlink:label="loc_MIRAPaymentOfDeferredOfferingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_MIRAPaymentOfDeferredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="999007 - Disclosure - Description of business and summary of significant accounting policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/PrepaidExpenses" xlink:title="999008 - Disclosure - Prepaid expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/LicenseAgreementRelatedParty" xlink:title="999009 - Disclosure - License agreement, related party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/AssetAcquisitionAndShort-termInvestmentRelatedParty" xlink:title="999010 - Disclosure - Asset acquisition and short-term investment &#8211; related party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="999011 - Disclosure - Related party transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="999012 - Disclosure - Commitments and contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/StockholdersEquity" xlink:title="999013 - Disclosure - Stockholders&#8217; equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/SegmentInformation" xlink:title="999014 - Disclosure - Segment information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/SubsequentEvents" xlink:title="999015 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999016 - Disclosure - Description of business and summary of significant accounting policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="999017 - Disclosure - Description of business and summary of significant accounting policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/PrepaidExpensesTables" xlink:title="999018 - Disclosure - Prepaid expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/AssetAcquisitionAndShort-termInvestmentRelatedPartyTables" xlink:title="999019 - Disclosure - Asset acquisition and short-term investment &#8211; related party (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/StockholdersEquityTables" xlink:title="999020 - Disclosure - Stockholders&#8217; equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/SegmentInformationTables" xlink:title="999021 - Disclosure - Segment information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/ScheduleOfDilutedNetLossPerShareAttributedToCommonStockDetails" xlink:title="999022 - Disclosure - Schedule of diluted net loss per share attributed to common stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999023 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/ScheduleOfPrepaidExpensesDetails" xlink:title="999024 - Disclosure - Schedule of prepaid expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:title="999025 - Disclosure - License agreement, related party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/ScheduleOfConsolidatedFinancialStatementsDetails" xlink:title="999026 - Disclosure - Schedule of consolidated financial statements (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/AssetAcquisitionAndShort-termInvestmentRelatedPartyDetailsNarrative" xlink:title="999027 - Disclosure - Asset acquisition and short-term investment &#8211; related party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999028 - Disclosure - Related party transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/ScheduleOfOptionActivityDetails" xlink:title="999029 - Disclosure - Schedule of option activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/ScheduleOfRestrisctedStockUnitActivityDetails" xlink:title="999030 - Disclosure - Schedule of restriscted stock unit activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999031 - Disclosure - Schedule of warrant activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="999032 - Disclosure - Stockholders&#8217; equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/ScheduleOfSegmentExpensesAndOtherSegmentExpensesDetails" xlink:title="999033 - Disclosure - Schedule of segment expenses and other segment expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/SegmentInformationDetailsNarrative" xlink:title="999034 - Disclosure - Segment information (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mirapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:title="999035 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
